Bender Robert & Associates
- SEC CIK
- 0000894300
- Latest filing
- Jul 30, 2026
BCRX holding history
Biocryst Pharmaceuticals Inc in every 13F filed by Bender Robert & Associates, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
BCRX overviewAll 13F holders of BCRXFull Q2 2026 holdings
- Shares (Q2 2026)
- 0
- Sold out in Q2 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 10
- Since Q2 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 0 | $0 | 0.0% | −23,710−100.0% | Sold out | Holders |
| Q1 2026 | 23,710 | $225.7K | 0.1% | +23,710 | New | Holders |
| Q4 2025 | 0 | $0 | 0.0% | −23,710−100.0% | Sold out | Holders |
| Q3 2025 | 23,710 | $180.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2025 | 23,710 | $212.4K | <0.1% | +23,710 | New | Holders |
| Q1 2025 | 0 | $0 | 0.0% | −23,710−100.0% | Sold out | Holders |
| Q4 2024 | 23,710 | $178.3K | <0.1% | +23,710 | New | Holders |
| Q1 2024 | 0 | $0 | 0.0% | −56,600−100.0% | Sold out | Holders |
| Q4 2023 | 56,600 | $339.0K | 0.1% | 00.0% | Unchanged | Holders |
| Q3 2023 | 56,600 | $400.7K | 0.1% | −12,000−17.5% | Reduced | Holders |
| Q2 2023 | 68,600 | $482.9K | 0.1% | 00.0% | Unchanged | Holders |
| Q1 2023 | 68,600 | $572.1K | 0.2% | +68,600 | New | Holders |
| Q4 2022 | 0 | $0 | 0.0% | −68,600−100.0% | Sold out | Holders |
| Q3 2022 | 68,600 | $864.0K | 0.3% | 00.0% | Unchanged | Holders |
| Q2 2022 | 68,600 | $726.0K | 0.3% | +68,600 | New | Holders |